U.S. FDA issues observation to Aurobindo Pharma arm’s API unit
The U.S. FDA has issued a procedural observation to Apitoria Pharma, a subsidiary of Aurobindo Pharma, following an inspection of its API manufacturing unit in Sangareddy. The company stated it will respond to the regulatory findings within the required timeframe.
Why it matters
Regulatory oversight of pharmaceutical manufacturing is critical for maintaining global drug safety and quality standards.
An active pharmaceutical ingredient (API) manufacturing facility of Aurobindo Pharma subsidiary Apitoria Pharma near Hyderabad has been issued an observation by the U.S. Food and Drug Administration (U.S. FDA).
Apitoria Pharma’s Unit-II, an API manufacturing facility, in Sangareddy district, was inspected from September 7-15. “The inspection concluded with one observation, which is procedural in nature and we will respond to the U.S. FDA within the stipulated timeline,” Aurobindo Pharma said in a filing on Tuesday.
Published - September 15, 2026 08:44 pm IST
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in